Advanced Alzheimer's disease
About
The etiology and treatment dilemma of advanced AD are multi-layered. The amyloid cascade hypothesis holds that the accumulation of Aβ42 to form extracellular senile plaques is the core trigger, while the hyperphosphorylation of tau protein to form neurofibrillary tangles (NFTs) is directly linked to neuron death and cognitive decline. Core target dilemmas: ①Aβ clearance cannot reverse the synaptic loss and neuronal apoptosis that have occurred;② The correlation between tau protein NFTs and cognitive severity is much higher than that of Aβ, but the development of tau-targeted drugs has repeatedly failed;③ Neuroinflammation is receiving increasing attention as an independent pathogenic pathway, and related drugs are still in their early stages.
Features & Symptoms
- A large number of neurons in the hippocampus and cortex died
- Complete loss of memory, cognition, and language functions
- Eventually bedridden
- Complicated infections such as pneumonia and pressure sores
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| New generation of anti-A β monoclonal antibody immunotherapy | Lecanemab (FDA approved in 2023) and donanemab (approved in 2024) have confirmed that clearance of Aβ delays early cognitive decline by approximately 27-35%, but has little effect in advanced patients and carries a risk of ARIA cerebral edema/microbleeding. | FDA批准 | $300K - $700K/年 |
| Tau protein targeted immunization/gene therapy | Targeting tau pathology in advanced AD, which is highly correlated with cognitive severity: ASO reduces tau protein mRNA levels;tau protein vaccines induce the production of anti-tau antibodies; and semorinemab targets the N-terminal tau protein. | Phase II | $250K - $600K/年 |
| Advanced palliative care + cognitive rehabilitation comprehensive package | A comprehensive plan for patients with advanced AD with improving quality of life as the core: a 24-hour professional nursing team manages daily life; multi-sensory stimulation therapy and music therapy maintains residual cognitive function; transcranial direct current stimulation combined with cognitive training enhances neural plasticity. | 临床应用 | $180K - $450K/年 |
Prognosis
Died due to complications 1-3 years after entering advanced stage
Additional Notes
Notes: Treatment window prompt: Lecanemab and Donanemab only affect early AD (Mild cognitive impairment or mild dementia) Effective, and palliative care should be the main focus for advanced patients; genetic testing recommendations: ARIA when using Lecanemab in patients homozygous for APOE ε4 The risk of (amyloid-related imaging abnormalities) is significantly increased, requiring enhanced MRI monitoring;ARIA monitoring: Cranial MRI monitoring for ARIA-E (cerebral edema) and ARIA-H (microbleeding) is required before starting anti-A β therapy and every 3-6 months during treatment; Safety warning: Anticoagulants need to be suspended during anti-A β therapy, and infusions need to be suspended when ARIA symptoms occur; palliative care: Terminally ill patients require a professional nursing team to manage dysphagia, pneumonia risk and behavioral symptoms. Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: Phase II/III clinical. Prognosis: Death due to complications 1-3 years after entering advanced stage.
Frequently Asked Questions
What is Advanced Alzheimer's disease?
The etiology and treatment dilemma of advanced AD are multi-layered. The amyloid cascade hypothesis holds that the accumulation of Aβ42 to form extracellular senile plaques is the core trigger, while the hyperphosphorylation of tau protein to form neurofibrillary tangles (NFTs) is directly linked to neuron death and cognitive decline. Core target dilemmas: ①Aβ clearance cannot reverse the synaptic loss and neuronal apoptosis that have occurred;② The correlation between tau protein NFTs and cognitive severity is much higher than that of Aβ, but the development of tau-targeted drugs has repeatedly failed;③ Neuroinflammation is receiving increasing attention as an independent pathogenic pathway, and related drugs are still in their early stages.
What are the symptoms of Advanced Alzheimer's disease?
A large number of neurons in the hippocampus and cortex died,Complete loss of memory, cognition, and language functions,Eventually bedridden,Complicated infections such as pneumonia and pressure sores
How is Advanced Alzheimer's disease treated?
New generation of anti-A β monoclonal antibody immunotherapy: Lecanemab (FDA approved in 2023) and donanemab (approved in 2024) have confirmed that clearance of Aβ delays early cognitive decline by approximately 27-35%, but has little effect in advanced patients and carries a risk of ARIA cerebral edema/microbleeding.; Tau protein targeted immunization/gene therapy: Targeting tau pathology in advanced AD, which is highly correlated with cognitive severity: ASO reduces tau protein mRNA levels;tau protein vaccines induce the production of anti-tau antibodies; and semorinemab targets the N-terminal tau protein.; Advanced palliative care + cognitive rehabilitation comprehensive package: A comprehensive plan for patients with advanced AD with improving quality of life as the core: a 24-hour professional nursing team manages daily life; multi-sensory stimulation therapy and music therapy maintains residual cognitive function; transcranial direct current stimulation combined with cognitive training enhances neural plasticity.
What is the prognosis for Advanced Alzheimer's disease?
Died due to complications 1-3 years after entering advanced stage